AKYA - Akoya Biosciences, Inc.
After hours:
| Previous close | 5.70 |
| Open | 5.78 |
| Bid | 5.91 x 900 |
| Ask | 5.96 x 800 |
| Day's range | 5.71 - 6.08 |
| 52-week range | 5.27 - 16.57 |
| Volume | |
| Avg. volume | 115,825 |
| Market cap | 229.665M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.94 |
| Earnings date | 07 Aug 2023 - 11 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.14 |
ZacksAkoya Biosciences (AKYA) Reports Q1 Loss, Tops Revenue Estimates
Akoya (AKYA) delivered earnings and revenue surprises of -6.52% and 5.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Simply Wall St.Is Akoya Biosciences, Inc. (NASDAQ:AKYA) Trading At A 34% Discount?
Key Insights The projected fair value for Akoya Biosciences is US$10.79 based on 2 Stage Free Cash Flow to Equity Akoya...
- Simply Wall St.
A Piece Of The Puzzle Missing From Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Share Price
It's not a stretch to say that Akoya Biosciences, Inc.'s ( NASDAQ:AKYA ) price-to-sales (or "P/S") ratio of 3.6x right...
- Simply Wall St.
Akoya Biosciences Full Year 2022 Earnings: EPS Misses Expectations
Akoya Biosciences ( NASDAQ:AKYA ) Full Year 2022 Results Key Financial Results Revenue: US$74.9m (up 36% from FY 2021...
ZacksAkoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates
Akoya (AKYA) delivered earnings and revenue surprises of -21.95% and 1.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksWill Akoya Biosciences (AKYA) Report Negative Earnings Next Week? What You Should Know
Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireAgilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
SANTA CLARA, Calif, & MARLBOROUGH, Mass., January 06, 2023--Agilent Technologies, Inc. (NYSE: A) today announced a partnership with Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, to develop multiplex-immunohistochemistry diagnostic solutions for tissue analysis and to commercialize workflow solutions for multiplex assays in the clinical research market. Integrating Agilent’s Dako Omnis (autostaining instrument) and Akoya’s PhenoImager® HT (imaging platform) for multiplex c
- Simply Wall St.
Institutions own 23% of Akoya Biosciences, Inc. (NASDAQ:AKYA) shares but private equity firms control 49% of the company
A look at the shareholders of Akoya Biosciences, Inc. ( NASDAQ:AKYA ) can tell us which group is most powerful. We can...
ZacksAkoya Biosciences (AKYA) Reports Q3 Loss, Tops Revenue Estimates
Akoya (AKYA) delivered earnings and revenue surprises of -17.50% and 5.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Akoya Biosciences (NASDAQ:AKYA) investors are sitting on a loss of 10% if they invested a year ago
It's normal to be annoyed when stock you own has a declining share price. But in the short term the market is a voting...
Motley FoolAkoya Biosciences, Inc. (AKYA) Q2 2022 Earnings Call Transcript
Thank you for standing by, and welcome to the Akoya Biosciences second quarter 2022 earnings conference call. On the call today, we have Brian McKelligon, chief executive officer; and Joe Driscoll, chief financial officer. Earlier today, Akoya released financial results for the second quarter ended June 30, 2022.
- Zacks
Akoya Biosciences (AKYA) Reports Q2 Loss, Tops Revenue Estimates
Akoya (AKYA) delivered earnings and revenue surprises of -38.24% and 5.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
What Kind Of Investors Own Most Of Akoya Biosciences, Inc. (NASDAQ:AKYA)?
If you want to know who really controls Akoya Biosciences, Inc. ( NASDAQ:AKYA ), then you'll have to look at the makeup...
ZacksAcadia (ACAD) Surges 15.5%: Is This an Indication of Further Gains?
Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
